A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Plain-language summary

This observational study evaluates long-term safety outcomes in patients who previously received at least one dose of RP1, RP2, or RP3. Patients who completed or discontinued the parent study with these products can take part; no treatment is given, as this is a follow-up-only study. It is a study with no applicable phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Replimune, Inc.

Intervention

Observational study with no interventions

Start date

12/12/2025

Estimated completion

12/1/2035

Countries

United States, Australia

Related genes

Locations

• La Jolla, United States
• Southport, Australia

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Patients are eligible for inclusion in the study only if they meet all of the following criteria:

1. Patient has received at least 1 dose of an RPx product and has completed or discontinued participation in the parent study.
2. Patient or patient's legal guardian has provided signed informed consent (or assent) as , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

Patients are excluded from the study if the following criterion applies:

1\. Cannot comply with the requirements of the study.